We are leading the science behind type 2 inflammation with a first-in-class treatment and robust pipeline of potential new medicines for chronic dermatological and respiratory diseases.
Our research of diseases driven by type 2 inflammation is a major area of focus for us and one in which we’ve already made a significant impact on the lives of patients. In collaboration with Regeneron, we have the first and only biologic treatment approved for moderate-to-severe atopic dermatitis for adults, adolescents and children (6-11 years of age). Our treatment is also approved for adults and adolescents with moderate-to-severe asthma and adults with moderate-to-severe chronic rhinosinusitis with nasal polyps. We are currently studying our treatment for use in additional dermatological diseases including chronic spontaneous urticaria, prurigo nodularis and bullous pemphigoid, as well as pediatric asthma, COPD and eosinophilic esophagitis.
Our immunology portfolio also includes our approved treatment for adults with moderate-to-severe rheumatoid arthritis.
Above from left to right: Gerard, rheumatoid arthritis, France; Miwako, atopic dermatitis, Japan; Jeff, asthma, Canada
Understand AD is a national awareness campaign focused on educating people about moderate-to-severe atopic dermatitis (AD), a chronic form of eczema that can be serious. By educating people about the physical and quality of life impact of atopic dermatitis, Understand AD will give a voice to and empower the people living with the disease.